RECOMBINANT ANTIGEN AGAINST ZIKA / DENGUE VIRUS, AND ITS VACCINE COMPOSITION AND USE

Abstract

A recombinant antigen against Zika / Dengue virus, and a vaccine composition thereof and its use. The recombinant antigen is obtained by introducing a specific mutation into the FL fusion loop region and optionally the non-FL fusion loop region of the E protein of a wild-type Zika / Dengue virus. By introducing the specific mutation, the FL epitope of the recombinant antigen is disrupted, which can prevent the induction of antibodies against the FL epitope; thus, the purpose of reducing or eliminating the ADE effect is achieved. In addition, the recombinant antigen has the correct conformation of the E protein, has a protein expression level similar to or higher than that of a wild-type, and can induce a relatively high titer of specific binding antibodies and neutralizing antibodies in the animal body, so that effective immune protection can be provided, and good clinical application value and industrialization prospects are achieved.